Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-07-19

AUTHORS

David L. Chan, Diego Ferone, Manuela Albertelli, Nick Pavlakis, Eva Segelov, Simron Singh

ABSTRACT

Background/PurposeSomatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting.MethodsEligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively.ResultsEighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0–14%). Rates of biochemical improvement (27–100%) and symptom improvement (23–100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues.ConclusionsThe current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours. More... »

PAGES

366-375

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12020-017-1360-z

DOI

http://dx.doi.org/10.1007/s12020-017-1360-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090776379

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28726183


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestinal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptides, Cyclic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Somatostatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Burden", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Sydney Medical School, University of Sydney, Camperdown, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada", 
            "Sydney Medical School, University of Sydney, Camperdown, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chan", 
        "givenName": "David L.", 
        "id": "sg:person.01372670252.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372670252.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferone", 
        "givenName": "Diego", 
        "id": "sg:person.0673454645.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673454645.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Albertelli", 
        "givenName": "Manuela", 
        "id": "sg:person.01072154657.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072154657.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.412703.3", 
          "name": [
            "Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavlakis", 
        "givenName": "Nick", 
        "id": "sg:person.01277354237.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354237.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Monash Health and Monash University, Caulfield East, VIC, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1002.3", 
          "name": [
            "Medical Oncology, Monash Health and Monash University, Caulfield East, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Segelov", 
        "givenName": "Eva", 
        "id": "sg:person.0714634276.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714634276.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "Simron", 
        "id": "sg:person.0750131705.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750131705.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12630-012-9879-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047971999", 
          "https://doi.org/10.1007/s12630-012-9879-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-011-0062-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028390274", 
          "https://doi.org/10.1007/s12325-011-0062-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.3275/7869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078423857", 
          "https://doi.org/10.3275/7869"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-19", 
    "datePublishedReg": "2017-07-19", 
    "description": "Background/PurposeSomatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting.MethodsEligible trials (using more than 30\u2009mg octreotide or 120\u2009mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively.ResultsEighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0\u201314%). Rates of biochemical improvement (27\u2013100%) and symptom improvement (23\u2013100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues.ConclusionsThe current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12020-017-1360-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1112251", 
        "issn": [
          "1355-008X", 
          "1559-0100"
        ], 
        "name": "Endocrine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "57"
      }
    ], 
    "keywords": [
      "gastroenteropancreatic neuroendocrine tumors", 
      "disease control rate", 
      "somatostatin analogues", 
      "neuroendocrine tumors", 
      "control rate", 
      "response rate", 
      "metastatic gastroenteropancreatic neuroendocrine tumors", 
      "antiproliferative effects", 
      "open-label trial design", 
      "objective response rate", 
      "definition of response", 
      "ConclusionsThe current evidence", 
      "risk of bias", 
      "common toxicities", 
      "symptom control", 
      "systemic therapy", 
      "abdominal discomfort", 
      "symptomatic improvement", 
      "dose escalation", 
      "biochemical improvement", 
      "symptom improvement", 
      "prospective study", 
      "ResultsEighteen studies", 
      "tumor response", 
      "unexpected toxicities", 
      "current evidence", 
      "trial design", 
      "clinical practice", 
      "small study", 
      "MethodsEligible trials", 
      "biochemical responses", 
      "systematic review", 
      "disease control", 
      "tumors", 
      "response outcomes", 
      "hormonal control", 
      "lower rates", 
      "conference proceedings", 
      "toxicity", 
      "trials", 
      "significant rate", 
      "outcomes", 
      "response", 
      "cholelithiasis", 
      "EMBASE", 
      "diarrhea", 
      "patients", 
      "mixed results", 
      "MEDLINE", 
      "therapy", 
      "symptoms", 
      "study", 
      "control", 
      "rate", 
      "demographics", 
      "discomfort", 
      "efficacy", 
      "treatment", 
      "risk", 
      "improvement", 
      "escalation", 
      "analogues", 
      "safety", 
      "effect", 
      "review", 
      "aim", 
      "fatigue", 
      "population", 
      "setting", 
      "cornerstone", 
      "evidence", 
      "database", 
      "role", 
      "above setting", 
      "need", 
      "practice", 
      "exact rate", 
      "bias", 
      "results", 
      "definition", 
      "proceedings", 
      "design"
    ], 
    "name": "Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review", 
    "pagination": "366-375", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090776379"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12020-017-1360-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28726183"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12020-017-1360-z", 
      "https://app.dimensions.ai/details/publication/pub.1090776379"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_751.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12020-017-1360-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12020-017-1360-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12020-017-1360-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12020-017-1360-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12020-017-1360-z'


 

This table displays all metadata directly associated to this object as RDF triples.

251 TRIPLES      21 PREDICATES      122 URIs      111 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12020-017-1360-z schema:about N062f5d24632949ab9e6c5576b00cf46a
2 N13a9ddc17f874edea8ba6962c64245c0
3 N16743d6f02da41528afdd29d9ae9c84d
4 N1d62c3c79d2245f58596575348930dab
5 N477135722f9845ae8501e897c0279cf3
6 N603ebd704c1f4b02b68cfb737b1faccc
7 N670e6e6a742c4f81a8f0491448f7c5c4
8 N6effaac082a849b084f1d81038d14f84
9 N8096d3d640f5408083c5eee06d27e163
10 N8858ef86160048d4990274e49d5b204f
11 N8f67652c37294eabbad80c0fcb54519f
12 Necd5c211ad8f425887944d501152a813
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N835dc990014048b185b45610818da657
16 schema:citation sg:pub.10.1007/s12325-011-0062-9
17 sg:pub.10.1007/s12630-012-9879-1
18 sg:pub.10.3275/7869
19 schema:datePublished 2017-07-19
20 schema:datePublishedReg 2017-07-19
21 schema:description Background/PurposeSomatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting.MethodsEligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively.ResultsEighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0–14%). Rates of biochemical improvement (27–100%) and symptom improvement (23–100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues.ConclusionsThe current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.
22 schema:genre article
23 schema:isAccessibleForFree false
24 schema:isPartOf N96b17b727b244c8eae0363a97dd73262
25 Nd0a3b873dbe14314802e7b6936073f02
26 sg:journal.1112251
27 schema:keywords ConclusionsThe current evidence
28 EMBASE
29 MEDLINE
30 MethodsEligible trials
31 ResultsEighteen studies
32 abdominal discomfort
33 above setting
34 aim
35 analogues
36 antiproliferative effects
37 bias
38 biochemical improvement
39 biochemical responses
40 cholelithiasis
41 clinical practice
42 common toxicities
43 conference proceedings
44 control
45 control rate
46 cornerstone
47 current evidence
48 database
49 definition
50 definition of response
51 demographics
52 design
53 diarrhea
54 discomfort
55 disease control
56 disease control rate
57 dose escalation
58 effect
59 efficacy
60 escalation
61 evidence
62 exact rate
63 fatigue
64 gastroenteropancreatic neuroendocrine tumors
65 hormonal control
66 improvement
67 lower rates
68 metastatic gastroenteropancreatic neuroendocrine tumors
69 mixed results
70 need
71 neuroendocrine tumors
72 objective response rate
73 open-label trial design
74 outcomes
75 patients
76 population
77 practice
78 proceedings
79 prospective study
80 rate
81 response
82 response outcomes
83 response rate
84 results
85 review
86 risk
87 risk of bias
88 role
89 safety
90 setting
91 significant rate
92 small study
93 somatostatin analogues
94 study
95 symptom control
96 symptom improvement
97 symptomatic improvement
98 symptoms
99 systematic review
100 systemic therapy
101 therapy
102 toxicity
103 treatment
104 trial design
105 trials
106 tumor response
107 tumors
108 unexpected toxicities
109 schema:name Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review
110 schema:pagination 366-375
111 schema:productId N27de2cda45cc41f293d868d2db0a30f5
112 N93b0a4e8cbee4597a110c5f52c9c69b6
113 Nca6148ccdb084e79817d38528044b0af
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090776379
115 https://doi.org/10.1007/s12020-017-1360-z
116 schema:sdDatePublished 2022-11-24T21:03
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N0606ca6d1d384ba88501b248c2be4deb
119 schema:url https://doi.org/10.1007/s12020-017-1360-z
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N0606ca6d1d384ba88501b248c2be4deb schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N062f5d24632949ab9e6c5576b00cf46a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Pancreatic Neoplasms
127 rdf:type schema:DefinedTerm
128 N13a9ddc17f874edea8ba6962c64245c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Stomach Neoplasms
130 rdf:type schema:DefinedTerm
131 N147f3d02c0fc45b4b1e0f7a95c841c6e rdf:first sg:person.0673454645.34
132 rdf:rest N6e270808597240debb4bf7e3729292fa
133 N16743d6f02da41528afdd29d9ae9c84d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Octreotide
135 rdf:type schema:DefinedTerm
136 N1d62c3c79d2245f58596575348930dab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antineoplastic Agents
138 rdf:type schema:DefinedTerm
139 N27de2cda45cc41f293d868d2db0a30f5 schema:name dimensions_id
140 schema:value pub.1090776379
141 rdf:type schema:PropertyValue
142 N2d80ab41a3cb46168fbf8b37adbe921d rdf:first sg:person.0750131705.21
143 rdf:rest rdf:nil
144 N477135722f9845ae8501e897c0279cf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Neuroendocrine Tumors
146 rdf:type schema:DefinedTerm
147 N603ebd704c1f4b02b68cfb737b1faccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N670e6e6a742c4f81a8f0491448f7c5c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Somatostatin
152 rdf:type schema:DefinedTerm
153 N6e270808597240debb4bf7e3729292fa rdf:first sg:person.01072154657.57
154 rdf:rest Nbab64e7770d9425ea84f2c4012b3f0c6
155 N6effaac082a849b084f1d81038d14f84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Dose-Response Relationship, Drug
157 rdf:type schema:DefinedTerm
158 N8096d3d640f5408083c5eee06d27e163 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Reproducibility of Results
160 rdf:type schema:DefinedTerm
161 N835dc990014048b185b45610818da657 rdf:first sg:person.01372670252.90
162 rdf:rest N147f3d02c0fc45b4b1e0f7a95c841c6e
163 N8858ef86160048d4990274e49d5b204f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Tumor Burden
165 rdf:type schema:DefinedTerm
166 N8f67652c37294eabbad80c0fcb54519f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Peptides, Cyclic
168 rdf:type schema:DefinedTerm
169 N93b0a4e8cbee4597a110c5f52c9c69b6 schema:name doi
170 schema:value 10.1007/s12020-017-1360-z
171 rdf:type schema:PropertyValue
172 N96b17b727b244c8eae0363a97dd73262 schema:volumeNumber 57
173 rdf:type schema:PublicationVolume
174 Nbab64e7770d9425ea84f2c4012b3f0c6 rdf:first sg:person.01277354237.30
175 rdf:rest Ncd2ebb16784543a5948ff2c8b3d93841
176 Nca6148ccdb084e79817d38528044b0af schema:name pubmed_id
177 schema:value 28726183
178 rdf:type schema:PropertyValue
179 Ncd2ebb16784543a5948ff2c8b3d93841 rdf:first sg:person.0714634276.97
180 rdf:rest N2d80ab41a3cb46168fbf8b37adbe921d
181 Nd0a3b873dbe14314802e7b6936073f02 schema:issueNumber 3
182 rdf:type schema:PublicationIssue
183 Necd5c211ad8f425887944d501152a813 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Intestinal Neoplasms
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:journal.1112251 schema:issn 1355-008X
193 1559-0100
194 schema:name Endocrine
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01072154657.57 schema:affiliation grid-institutes:None
198 schema:familyName Albertelli
199 schema:givenName Manuela
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072154657.57
201 rdf:type schema:Person
202 sg:person.01277354237.30 schema:affiliation grid-institutes:grid.412703.3
203 schema:familyName Pavlakis
204 schema:givenName Nick
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354237.30
206 rdf:type schema:Person
207 sg:person.01372670252.90 schema:affiliation grid-institutes:grid.1013.3
208 schema:familyName Chan
209 schema:givenName David L.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372670252.90
211 rdf:type schema:Person
212 sg:person.0673454645.34 schema:affiliation grid-institutes:None
213 schema:familyName Ferone
214 schema:givenName Diego
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673454645.34
216 rdf:type schema:Person
217 sg:person.0714634276.97 schema:affiliation grid-institutes:grid.1002.3
218 schema:familyName Segelov
219 schema:givenName Eva
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714634276.97
221 rdf:type schema:Person
222 sg:person.0750131705.21 schema:affiliation grid-institutes:grid.413104.3
223 schema:familyName Singh
224 schema:givenName Simron
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750131705.21
226 rdf:type schema:Person
227 sg:pub.10.1007/s12325-011-0062-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028390274
228 https://doi.org/10.1007/s12325-011-0062-9
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s12630-012-9879-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047971999
231 https://doi.org/10.1007/s12630-012-9879-1
232 rdf:type schema:CreativeWork
233 sg:pub.10.3275/7869 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078423857
234 https://doi.org/10.3275/7869
235 rdf:type schema:CreativeWork
236 grid-institutes:None schema:alternateName Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
237 schema:name Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
238 rdf:type schema:Organization
239 grid-institutes:grid.1002.3 schema:alternateName Medical Oncology, Monash Health and Monash University, Caulfield East, VIC, Australia
240 schema:name Medical Oncology, Monash Health and Monash University, Caulfield East, VIC, Australia
241 rdf:type schema:Organization
242 grid-institutes:grid.1013.3 schema:alternateName Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
243 schema:name Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
244 Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
245 rdf:type schema:Organization
246 grid-institutes:grid.412703.3 schema:alternateName Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia
247 schema:name Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia
248 rdf:type schema:Organization
249 grid-institutes:grid.413104.3 schema:alternateName Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
250 schema:name Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
251 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...